

## Prevalence a charakteristika karcinomů prostaty detekovaných screeningem při nízkých hladinách prostatického specifického antigenu: jsou agresivní nebo nevýznamné?

CLAARTJE GOSSELAAR, MONIQUE J. ROOBOL a FRITZ H. SCHRÖDER

Department of Urology (Screening unit for prostate cancer), Erasmus University, Rotterdam, the Netherlands

### LITERATURA

- 1 **Hsing AW, Tsao L, Devesa SS.** International trends and patterns of prostate cancer incidence and mortality. *Int J Cancer* 2000; **85**: 60–7
- 2 **Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ.** Cancer statistics 2003. *CA Cancer J Clin* 2003; **53**: 5–26
- 3 **Scardino PT, Weaver R, Hudson MA.** Early detection of prostate cancer. *Hum Pathol* 1992; **23**: 211–22
- 4 **Scardino PT.** Early detection of prostate cancer. *Urol Clin North Am* 1989; **16**: 635–55
- 5 **Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP.** Localized prostate cancer. Relationship of tumor Volume to clinical significance for treatment of prostate cancer. *Cancer* 1993; **71** (Suppl. 2): 933–8
- 6 **Epstein JI, Walsh PC, Carmichael M, Brendler CB.** Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. *JAMA* 1994; **271**: 368–74
- 7 **Thompson IM, Pauler DK, Goodman PJ et al.** Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. *N Engl J Med* 2004; **350**: 2239–46
- 8 **Carter HB.** Prostate cancers in men with low PSA levels – must we find them? *N Engl J Med* 2004; **350**: 2292–4
- 9 **Schröder FH, Roobol-Bouts M, Vis AN, van der Kwast T, Kranse R.** Prostatespecific antigen-based early detection of prostate cancer – validation of screening without rectal examination. *Urology* 2001; **57**: 83–90
- 10 **Raaijmakers R, Blijenberg BG, Finlay JA et al.** Prostate cancer detection in the prostate specific antigen range of 2.0–3.9 ng/ml: value of percent free prostate specific antigen on tumor detection and tumor aggressiveness. *J Urol* 2004; **171**: 2245–9
- 11 **Kranse R, Beemsterboer P, Rietbergen J, Habbema D, Hugosson J, Schröder FH.** Predictors for biopsy outcome in the European Randomized Study of Screening for Prostate Cancer (Rotterdam region). *Prostate* 1999; **39**: 316–22
- 12 **Rietbergen JB, Kranse R, Kirkels WJ, De Koning HJ, Schröder FH.** Evaluation of prostate-specific antigen, digital rectal examination and transrectal ultrasonography in population-based screening for prostate cancer: improving the efficiency of early detection. *Br J Urol* 1997; **79** (Suppl. 2): 57–63
- 13 **Franks LM.** Latent carcinoma of the prostate. *J Pathol Bacteriol* 1954; **68**: 603–16
- 14 **Edwards CN, Steinthorsson E, Nicholson D.** An autopsy study of latent prostatic cancer. *Cancer* 1953; **6**: 531–54
- 15 **Andrews.** Latent carcinoma of the prostate. *J Clin Pathol* 1949; **2**: 197–208
- 16 **Moore.** The morphology of small prostatic carcinoma. *J Urol* 1935; **33**: 224–34
- 17 **Hirst AE Jr, Bergman RT.** Carcinoma of the prostate in men 80 or more years old. *Cancer* 1954; **7**: 136–41
- 18 **Sakr WA, Haas GP, Cassin BF, Pontes JE, Crissman JD.** The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. *J Urol* 1993; **150**: 379–85
- 19 **Sakr WA, Ward C, Grignon DJ, Haas GP.** Epidemiology and molecular biology of early prostatic neoplasia. *Mol Urol* 2000; **4**: 109–13
- 20 **Sanchez-Chapado M, Olmedilla G, Cabeza M, Donat E, Ruiz A.** Prevalence of prostate cancer and prostatic intraepithelial neoplasia in Caucasian Mediterranean males: an autopsy study. *Prostate* 2003; **54**: 238–47
- 21 **Holund B.** Latent prostatic cancer in a consecutive autopsy series. *Scand J Urol Nephrol* 1980; **14**: 29–35
- 22 **Smith DS, Catalona WJ, Herschman JD.** Longitudinal screening for prostate cancer with prostate-specific antigen. *JAMA* 1996; **276**: 1309–15
- 23 **Beemsterboer PM, Kranse R, de Koning HJ, Habbema JD, Schröder FH.** Changing role of 3 screening modalities in the European Randomized Study Of Screening For Prostate Cancer (Rotterdam). *Int J Cancer* 1999; **84**: 437–41

- 24 **Bogdanowicz JF, Bentvelsen FM, Oosterom R, Schroeder FH.** Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia. *Scand J Urol Nephrol Suppl* 1991; **138**: 97-103
- 25 **Oosterom R, Bogdanowicz J, Schröder FH.** Evaluation of prostate-specific antigen in untreated prostatic carcinoma. *Eur Urol* 1989; **16**: 253-7
- 26 **Montie JE, Wood DP Jr, Pontes JE, Boyett JM, Levin HS.** Adenocarcinoma of the prostate in cystoprostatectomy specimens removed for bladder cancer. *Cancer* 1989; **63**: 381-5
- 27 **Ohori M, Wheeler TM, Dunn JK, Stamey TA, Scardino PT.** The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. *J Urol* 1994; **152**: 1714-20
- 28 **Kabalin JN, McNeal JE, Price HM, Freiha FS, Stamey TA.** Unsuspected adenocarcinoma of the prostate in patients undergoing cystoprostatectomy for other causes: incidence, histology and morphometric observations. *J Urol* 1989; **141**: 1091-4
- 29 **Ward JF, Bartsch G, Sebo TJ, Pinggera GM, Blute ML, Zincke H.** Pathologic characterization of prostate cancers with a very low serum prostate specific antigen (0-2 ng/mL) incidental to cystoprostatectomy: is PSA a useful indicator of clinical significance? *Urol Oncol* 2004; **22**: 40-7
- 30 **Gleason DF.** Classification of prostatic carcinomas. *Cancer Chemother Rep* 1966; **50**: 125-8
- 31 **Epstein JI.** Gleason score 2-4 adenocarcinoma of the prostate on needle biopsy: a diagnosis that should not be made. *Am J Surg Pathol* 2000; **24**: 477-8
- 32 **Narain V, Bianco FJ Jr, Grignon DJ, Sakr WA, Pontes JE, Wood DP Jr.** How accurately does prostate biopsy Gleason score predict pathologic findings and disease free survival? *Prostate* 2001; **49**: 185-90
- 33 **Catalona WJ, Bartsch G, Rittenhouse HG et al.** Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2-4 ng/ml prostate specific antigen. *J Urol* 2004; **171**: 2239-44
- 34 **McNeal JE, Bostwick DG, Kindrachuk RA, Redwine EA, Freiha FS, Stamey TA.** Patterns of progression in prostate cancer. *Lancet* 1986; **1**: 60-3
- 35 **Lowe BA, Listrom MB.** Incidental carcinoma of the prostate: an analysis of the predictors of progression. *J Urol* 1988; **140**: 1340-4
- 36 **Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM.** Biological determinants of cancer progression in men with prostate cancer. *JAMA* 1999; **281**: 1395-400
- 37 **Epstein JI, Carmichael M, Partin AW, Walsh PC.** Is tumor Volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup. *J Urol* 1993; **149**: 1478-81
- 38 **Kikuchi E, Scardino PT, Wheeler TM, Slawin KM, Ohori M.** Is tumor volume an independent prognostic factor in clinically localized prostate cancer? *J Urol* 2004; **172**: 508-11
- 39 **Stamey TA.** More information on prostate specific antigen and prostate cancer. *J Urol* 2003; **170**: 457-8
- 40 **Catalona WJ, Smith DS, Ornstein DK.** Prostate cancer detection in men with serum PSA concentrations of 2.6-4.0 ng/ mL and benign prostate examination. Enhancement of specificity with free PSA measurements. *JAMA* 1997; **277**: 1452-5
- 41 **Lodding P, Aus G, Bergdahl S et al.** Characteristics of screening detected prostate cancer in men 50-66 years old with 3-4 ng/ml prostate specific antigen. *J Urol* 1998; **159**: 899-903
- 42 **Hoedemaeker RF, Rietbergen JB, Kranse R, van der Kwast TH, Schröder FH.** Comparison of pathologic characteristics of T1c and non-T1c cancers detected in a population-based screening study, the European Randomized Study of Screening for Prostate Cancer. *World J Urol* 1997; **15**: 339-45
- 43 **Roobol MJ, Vries de SH, Schröder FH.** Final results of initial and second prostate cancer screening round of the European Randomized study of Screening for Prostate Cancer (Rotterdam). *J Urol* 2004; **165**: Abstract, 165
- 44 **Schröder FH, van der Maas P, Beemsterboer P et al.** Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. *J Natl Cancer Inst* 1998; **90**: 1817-23

Korespondence:  
Claartje Gosselaar,  
Department of Urology (Screening  
unit for prostate cancer),  
Room NH-227, PO Box 2040,  
3000 CA Rotterdam,  
the Netherlands.  
e-mail: c.gosselaar@erasmusmc.nl

Zkratky:  
**PCPT**, Prostate Cancer Prevention  
Trial; **ESRPC**, European  
Randomised study of Screening for  
Prostate Cancer.